Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

被引：7

作者：

Badros, Ashraf Z. ^{[1
]}

Hyjek, Elizabeth ^{[2
]}

Ma, Ning ^{[1
]}

Lesokhin, Alexander M. ^{[3
]}

Rapoport, Aaron P. ^{[1
]}

Kocoglu, Mehmet H. ^{[1
]}

Lederer, Emily ^{[4
]}

Philip, Sunita ^{[4
]}

Lesho, Patricia ^{[4
]}

Johnson, Ashlee ^{[4
]}

Dell, Cameron ^{[4
]}

Goloubeva, Olga ^{[4
]}

Singh, Zeba ^{[5
]}

机构：

[1] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD USA

[2] Univ Chicago, Dept Pathol, Chicago, IL USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, New York, NY USA

[4] Univ Maryland, Baltimore, MD USA

[5] Univ Maryland, Sch Med, Pathol, Baltimore, MD USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.490.490

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

490

引用

页数：5

共 50 条

[41] Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma
Brown, Emily
FUTURE ONCOLOGY, 2013, 9 (11) : 1684 - 1685
[42] Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol
Usmani, Saad
Waheed, Sarah
Szymonifka, Jackie
Panozzo, Susan
Petty, Nathan M.
Steward, Doug
Nair, Bijay
Alsayed, Yazan
Hoering, Antje
Crowley, John
Barlogie, Bart
BLOOD, 2011, 118 (21) : 1710 - 1710
[43] Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
Facon, Thierry
Lonial, Sagar
Weiss, Brendan M.
Suvannasankha, Attaya
Fay, Joseph
Arnulf, Bertrand
Ifthikharuddin, Jainulabdeen J.
de Boer, Carla
Wang, Jianping
Wu, Kaida
Chari, Ajai
Lentzsch, Suzanne
Schecter, Jordan
Krishnan, Amrita
BLOOD, 2017, 130
[44] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
White, Darrell
LeBlanc, Richard
Venner, Chritopher
Bahlis, Nizar J.
Lentzsch, Suzanne
Gasparetto, Cristina J.
Chen, Christine
Lipe, Brea
Sutherland, Heather
Tuchman, Sascha
Baljevic, Muhamed
Kotb, Rami
Sebag, Michael
Callander, Nancy
Bensinger, William
Kai, Kazuharu
Liu, Jianjun
Sheehan, Heidi
Estepan, Daniel Nova
Shah, Jatin
Schiller, Gary J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E55 - E55
[45] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
Kumar, Anupama
Rosenberg, Aaron S.
Padilla, Michelle
Shah, Nina
Sirianni, Lindsey
Liu, Lin
Cheng, Yuwei
Pittman, Emily
Tzachanis, Dimitrios
Larson, Sarah
Mulroney, Carolyn
Ball, Edward D.
Costello, Caitlin
BLOOD, 2022, 140 : 4436 - 4437
[46] EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Delgado, Julio
Zienowicz, Malgorzata
van Hennik, Paula Boudewina
Moreau, Alexandre
Gisselbrecht, Christian
Enzmann, Harald
Pignatti, Francesco
ONCOLOGIST, 2021, 26 (11): : 983 - 987
[47] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Yee, Andrew Jenho
Laubach, Jacob
Campagnaro, Erica Leigh
Lipe, Brea
Nadeem, Omar
Cole, Craig
O'Donnell, Elizabeth
Schlossman, Robert L.
Bianchi, Giada
Branagan, Andrew Robert
Shapiro, Samantha J.
Harrington, Cynthia C.
Burke, Jill N.
Gammon, Marilyn T.
Lively, Kathleen J.
Thorburn, Cassandra Ann
Mann, Mason L.
Lohr, Jens Guenter
Richardson, Paul G.
Raje, Noopur S.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[48] Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
Chen, Christine
Kotb, Rami
Sebag, Michael
LeBlanc, Richard
Sutherland, Heather J.
White, Darrell
Venner, Christopher P.
Kouroukis, Tom
Bergstrom, Debra
McCurdy, Arleigh
Lalancette, Marc
Bensinger, William
Lentzsch, Suzanne
Del Col, Aldo
Kauffman, Michael
Shacham, Sharon
Jeha, Jacqueline
Picklesimer, Carla
Saint-Martin, Jean-Richard
Choe-Juliak, Cassandra
Bahlis, Nizar J.
BLOOD, 2016, 128 (22)
[49] Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
Berenson, James R.
Stampleman, Laura
Bessudo, Alberto
Rosen, Peter
Klein, Leonard M.
Woliver, Thomas B. S.
Flam, Marshall S.
Eshaghian, Shahrooz
Nassir, Youram
Swift, Regina A.
Vescio, Robert A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[50] Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, Laurent
Kuhnowski, Frederique
Berge, Benoit
Roussel, Murielle
Escoffre-Barbe, Martine
Lafon, Ingrid
Facon, Thierry
Leleu, Xavier
Karlin, Lionel
Perrot, Aurore
Moreau, Philippe
Marit, Gerald
Stoppa, Anne-Marie
Royer, Bruno
Chaleteix, Carine
Tiab, Mourad
Araujo, Carla
Lenain, Pascal
Macro, Margaret
Voog, Eric
Benboubker, Lofti
Allangba, Olivier
Jourdan, Eric
Orsini-Piocelle, Frederique
Brechignac, Sabine
Eveillard, Jean-Richard
Belhadj, Karim
Wetterwald, Marc
Pegourie, Brigitte
Jaccard, Arnaud
Eisenmann, Jean-Claude
Glaisner, Sylvie
Mohty, Mohamad
Hulin, Cyrille
Avet-Loiseau, Herve
Mathiot, Claire
Attal, Michel
BLOOD, 2018, 132 (24) : 2555 - 2563

← 1 2 3 4 5 →